ALD 101

Drug Profile

ALD 101

Alternative Names: ALD-101

Latest Information Update: 13 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aldagen
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Metabolic disorders
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Metabolic disorders

Most Recent Events

  • 05 May 2014 Discontinued - Phase-III for Metabolic disorders in USA (IV)
  • 08 Feb 2012 Aldagen has been acquired by Cytomedix
  • 08 Dec 2009 Pharmacodynamics data from preclinical studies presented at the 51st Annual Meeting and Exposition of the American Society of Hematology (ASH-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top